AROA™

Aroa Biosurgery (ARX) – February 2026 BUSINESS UPDATE

• • • UNLOCKING REGENERATIVE HEALING FOR EVERY*BODY*

Important notice and disclaimer

AROA™

This presentation (**Presentation**) is dated 3 February 2026 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (**AROA** or the Company).

Information in this Presentation

The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. This Presentation has been prepared in conjunction with an oral presentation and should not be taken out of context. It does not contain all information relevant or necessary for an investment decision or that would be required to be included in a prospectus or other disclosure document under the Corporations Act for an offer of securities in Australia or in any other jurisdiction. This Presentation includes **GRAPHIC WOUND IMAGERY; VIEWER DISCRETION IS ADVISED.** This Presentation is intended for investor education purposes only and is not intended as a medical device advertisement (including, for the purposes of the New Zealand Medicines Act 1981). Products shown may not be available in your region. Results may vary. The content of this Presentation is provided as at the date of this Presentation (unless otherwise stated). Except as required by applicable law, AROA does not plan to publicly update or revise any information contained in, or provided with, this Presentation whether as a result of any new information, future events, changed circumstances or otherwise.

Not a prospectus or an offer of securities

This Presentation is not a prospectus or any other offering document under Australian law (or under the law of any other jurisdiction in which an offer of securities may be received. Nothing in this Presentation should be construed as an invitation, offer or recommendation of securities in AROA (or any of its subsidiaries) for subscription, purchase or sale in any jurisdiction. Potential investors should read this presentation in conjunction with AROA's other periodic and continuous disclosure announcements lodged with ASX and should rely solely on their own judgement, review and analysis when making an investment decision about AROA.

Future performance

Past performance information in this Presentation is given for illustrative purposes only and should not be relied upon (and is not) an indication of future performance. The Presentation contains certain "forward-looking statements". The words "forecast", "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. These statements are based on current expectations and assumptions regarding AROA's business and performance, the economy and other circumstances. As with any projection or forecast, forward-looking statements in this Presentation are inherently uncertain and susceptible to changes in circumstances. Opinions involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Actual results, performance or achievements may differ materially from those expressed or implied in forward looking statements and statements of opinion. In particular, market data reflects estimates only and investors are cautioned against placing undue reliance on it.

IP notice

AROA, Aroa Biosurgery, AROA ECM, Endoform, Myriad, Myriad Matrix, Morcells, Myriad Morcells, Myriad Ultra, Myriad Flow, Symphony and Enivo are trademarks of Aroa Biosurgery Limited. All other trademarks are properties of their respective owners. ©2025 Aroa Biosurgery Limited

CONTENTS

Myriad Trauma Study

01	**MASTRR** - the largest ongoing, prospective, multicenter observational study of bioscaffolds in complex reconstruction **- 450 patients are enrolled to date.**
02	**Trauma subgroup -** 49 patients (61 defects) in four U.S. Level 1 trauma centers.
03	Fully vascularized **tissue coverage** in a median of **22.5 days**, often with just **one application**, and **no** device related **complications**
04	Myriad **clinical outcomes** were **at least equivalent to, or better**, with **fewer complications and product applications** vs. reported outcomes[1] of other bioscaffolds
05	Demonstrates potential for **improved patient outcomes & reduced total cost of care** for hospitals

!. As per literature synthesis included in the study.

Symphony reimbursement

01 **Flat fee of 127.14/cm2** from 1st January '26

02 **LCDs withdrawn** removing limitation on number of applications and requirement for RCT. Expect both to be introduced in the future in some form.

03 **Market disruption expected** based on new pricing & likely introduction of RCT requirement in the future.

04 **Reimbursement policy is not settled** - may be further changes in '26.

05 **Symphony RCT concluded**. High level results expected to be announced by end Mar '26.

06 **Symphony is well positioned irrespective of likely changes** – pricing & evidence.

Symphony commercial strategy

01	**Hospital Outpatient Department** likely to benefit from reimbursement changes – fits with AROA's direct sales call point
02	**Symphony** is an **important addition** to direct team's sales portfolio
03	**Expansion opportunities through distribution partnerships** (Physician office, home health & mobile providers)

Momentum

01	**Increasing success** with **Myriad** in soft tissue reconstruction
02	**AROA ECM clinical evidence accumulating**
03	**Symphony is a significant new opportunity**
04	**TELABio** continues to be **significant contributor**

Guidance - towards the upper end

NZ$92-100m

Total Revenue

YoY CC growth 10 – 20%

(Myriad 25%+ YoY CC growth)

NZ$5-8m

Normalised EBITDA

Note: Guidance provided on constant currency basis (removes the impact of exchange rate movements). Guidance based on an average NZ$/US$ exchange rate of 0.60 (compared to the average exchange rate of 0.59 in FY25), US tariff rates remaining at 15% and no material decline in US medical procedure numbers or sustained disruption to AROA's manufacturing or transport activities.

AROA BIOSURGERY

Questions & Answers

AROA™

Thank you for attending

Eleonora de Vos

m +61 450 930 010
investor@aroa.com

Visit
www.aroa.com

www.linkedin.com/company/aroa-biosurgery-limited/

64 Richard Pearse Drive,
Auckland 2022, New Zealand

PO Box 107111, Auckland Airport,
Auckland 2150, New Zealand